Cytogen gets FDA approval for product licence application (PLA) supplement:
This article was originally published in Clinica
Executive Summary
The US FDA has approved Cytogen's PLA supplement for its OncoScint CR/OV, expanding the imaging agent's indications to include readministration to HAMA-negative patients at risk of cancer recurrence. OncoScint received FDA approval in December 1992 and is the only such agent approved for tumour imaging, claims Cytogen. There have been around 150,000 cases of colorectal cancer each year in the US since 1990, according to the American Cancer Society.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.